ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Silexion Therapeutics Corp
1.59
-0.0600
-3.64%
成交量:
2.08萬
成交額:
3.35萬
市值:
497.14萬
市盈率:
-0.06
高:
1.68
開:
1.68
低:
1.56
收:
1.65
52周最高:
26.70
52周最低:
1.51
股本:
312.66萬
流通股本:
275.35萬
量比:
1.31
換手率:
0.75%
股息:
- -
股息率:
- -
每股收益(TTM):
-25.2122
每股收益(LYR):
-395.3595
淨資產收益率:
-771.23%
總資產收益率:
-77.60%
市淨率:
0.71
市盈率(LYR):
0.00
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Silexion Therapeutics Corp盤中異動 大幅下挫5.14%報1.66美元
市场透视
·
02/11
Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋
美股速递
·
2025/12/02
Silexion Therapeutics 成功完成 Sil204 的毒理學研究,為胰腺癌的 2/3 階段臨牀試驗做好準備
美股速递
·
2025/11/25
Silexion Therapeutics Corp公布積極的人體細胞係數據,證實Sil204的泛KRAS活性,抑制率高達99.7%,並首次在胃癌中顯示療效
美股速递
·
2025/09/30
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.59,"timestamp":1770915648031,"preClose":1.65,"halted":0,"volume":20758,"delay":0,"changeRate":-0.036363636363636265,"floatShares":2753490,"shares":3126642,"eps":-25.2122,"marketStatus":"交易中","change":-0.06,"latestTime":"02-12 12:00:58 EST","open":1.68,"high":1.68,"low":1.555,"amount":33523.4725312,"amplitude":0.075758,"askPrice":1.6,"askSize":200,"bidPrice":1.5,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-25.2122,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.65,"preHourTrading":{"tag":"盘前","latestPrice":1.66,"preClose":1.65,"latestTime":"09:25 EST","volume":24,"amount":39.839999999999996,"timestamp":1770906300024,"change":0.01,"changeRate":0.006061,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.65,"preClose":1.65,"latestTime":"16:10 EST","volume":1,"amount":1.65,"timestamp":1770844205003,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.313236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-77.60%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":1.313236,"shares":3126642,"dividePrice":0,"high":1.68,"amplitude":0.075758,"preClose":1.65,"low":1.555,"week52Low":1.51,"pbRate":"0.71","week52High":26.7,"institutionHeld":0,"latestPrice":1.59,"committee":-0.904762,"eps":-25.2122,"divideRate":0,"volume":20758,"delay":0,"ttmEps":-25.2122,"open":1.68,"prevYearClose":1.92,"prevWeekClose":1.61,"prevMonthClose":1.83,"prevQuarterClose":1.92,"fiveDayClose":1.51,"twentyDayClose":2.12,"sixtyDayClose":2.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765861200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-02-10","current":-0.065445,"percent":0.207071,"low":-1.070842,"twenty":-0.602539,"median":-0.41656,"eighty":-0.124047,"high":-0.075397,"avg":-0.40123,"sd":0.252983,"marketCap":5471623},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-10","current":-0.591719,"twenty":-0.602539,"median":-0.41656,"eighty":-0.124047,"marketCap":5471623}],"updateTime":1770875198897},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610620679","title":"Silexion Therapeutics Corp盤中異動 大幅下挫5.14%報1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620679?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 01:34","pubTimestamp":1770744859,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日01时34分,Silexion Therapeutics Corp股票出现波动,股价急速下挫5.14%。截至发稿,该股报1.66美元/股,成交量2.9551万股,换手率0.95%,振幅6.86%。Silexion Therapeutics Corp股票所在的生物技术行业中,整体涨幅为0.14%。Silexion Therapeutics Corp公司简介:Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司,致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"1108369243","title":"Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108369243","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108369243?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 21:01","pubTimestamp":1764680504,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1186776790","title":"Silexion Therapeutics 成功完成 Sil204 的毒理學研究,為胰腺癌的 2/3 階段臨牀試驗做好準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1186776790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186776790?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 成功完成了 Sil204 的毒理学研究,这是一种下一代 RNA 静默疗法,为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1183341465","title":"Silexion Therapeutics Corp公布積極的人體細胞係數據,證實Sil204的泛KRAS活性,抑制率高達99.7%,並首次在胃癌中顯示療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183341465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183341465?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布公布积极的人体细胞系新数据,证实了其候选药物Sil204的泛KRAS活性。数据显示,该药物的抑制率高达99.7%,并首次在胃癌治疗中展现出积极效果。\n这项最新研究结果进一步验证了Sil204作为泛KRAS抑制剂的潜力,为该公司在肿瘤治疗领域的药物开发提供了重要支撑。特别值得关注的是,这是该药物首次在胃癌细胞中显示出治疗活性,为胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLXN\",params:#limit:6,delay:false,,,undefined,":[]}}